WO1997009434A1 - Nucleases specifiques de la structure de l'adn - Google Patents

Nucleases specifiques de la structure de l'adn Download PDF

Info

Publication number
WO1997009434A1
WO1997009434A1 PCT/GB1996/002218 GB9602218W WO9709434A1 WO 1997009434 A1 WO1997009434 A1 WO 1997009434A1 GB 9602218 W GB9602218 W GB 9602218W WO 9709434 A1 WO9709434 A1 WO 9709434A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide sequence
sequence according
wild
protein
codon
Prior art date
Application number
PCT/GB1996/002218
Other languages
English (en)
Inventor
David Malcolm James Lilley
Marie-Josèphe Emilie GIRAUD-PANIS
James Richard Gibson PÖHLER
Original Assignee
University Of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9518382.8A external-priority patent/GB9518382D0/en
Priority claimed from GBGB9614111.4A external-priority patent/GB9614111D0/en
Application filed by University Of Dundee filed Critical University Of Dundee
Priority to AU68862/96A priority Critical patent/AU6886296A/en
Publication of WO1997009434A1 publication Critical patent/WO1997009434A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to novel enzymes, in particular DNA structure-specific nucleases, and their use in diagnostics.
  • the phage resolving enzymes are primarily DNA structure- specific nucleases that cleave branched structures in DNA, such as helical junctions and bulges, (Duckett, D.R. , et al., Eur. J. Biochem. (1992) , 207, 285-295) . They also exhibit some activity against single-base mismatches (Solaro, P.C, et al., J. Molec. Biol. (1993) , 230, 868-877) . There has recently been considerable interest in these proteins as a means of detecting mismatches, and hence mutations, in heteroduplexed DNA. (Youil, R. ,
  • the random mutagenesis approach may not prove to be universal and indeed, attempts to use it in the context of other enzymes, notably the T4 endonuclease VII enzyme, has failed.
  • the wild-type gene of this enzyme is known (Tomaschewski et al, Nucl. Acids Res. (1988) 15, 3632- 3633) .
  • the invention provides a nucleotide sequence which encodes a DNA structure-specific nuclease but in which a codon for at least one amino acid residue has been changed as compared to the sequence of a wild-type nuclease and wherein the nuclease encoded by the sequence is less toxic to a host cell than said wild-type enzyme, and/or said nuclease does not have the catalytic activity of the wild-type enzyme but which retains the structure- selective DNA binding properties of the wild-type enzyme; provided that said DNA molecule does not encode a mutant of T7 endonuclease I selected from P54L P59S (double mutant) , E65K V64I (double mutant) , D55N, E35K or P59K.
  • the reduced toxicity of the nuclease means that the nucleotide sequence may be overproduced in a host cell without being toxic to that cell.
  • the said corresponding wild-type enzyme comprises T4 endonuclease VII and so the nucleotide sequence encodes a mutant of this enzyme.
  • the codon change involves the replacement of a codon for an acidic amino acid residue with a codon for a non-acidic residue.
  • a codon for a non-acidic residue For example, an asparatate or a glutamate residue may be replaced by a non-acidic residue such as alanine.
  • Such changes have been found to give rise to mutant nucleases which have both low toxicity (and can therefore be over expressed) and which lack catalytic activity.
  • a particular example of such nucleases are mutants of T4 endonuclease VII wherein the glutamate residue at position 86 in the amino acid sequence shown in Figure 1 is replaced with a non-acidic residue, in particular alanine.
  • An alternative codon change involves the replacement of a codon for a histidine residue with a threonine residue.
  • Nucleases obtained by expression of such nucleotide sequences have reduced toxicity as compared to wild-type.
  • it has been for a mutant of T4 endonuclease VII which has a threonine in place of the histidine at position 38 in the amino acid sequence as set out in Figure 1.
  • T4 endonuclease VII point mutants are also within the scope of the present invention either individually or in combination. They all have low toxicity when expressed in E. coli and exhibit structure selective binding to DNA junctions. In this way, the T4 endonuclease VII point mutants are useful as binding probes.
  • the mutation is referred to in the standard way by: the amino acid (in single letter code) to be replaced, the position in the amino acid sequence shown in Figure 1 and the amino acid (in single letter code) to be substituted.
  • D40A PA inactive 20 ⁇ 19 binds DNA junctions full zinc content
  • MBP binds DNA junctions
  • additional codon changes have been made in the sequence of the wild-type protein in order to optimise codon choice for the particular host cell.
  • optimisation for expression in E. coli include the replacement of leucine codons such as TTA or CTA are replaced by CTG, CTT or CTC. Other such changes would be apparent to the skilled person. Such optimisation will increase the levels of protein expression.
  • the nucleotide sequence of the invention may form part of a larger sequence.
  • the larger sequence encodes a translational fusion protein which include peptides which enable purification of the product to be effected using a single step affinity chromatography step.
  • a fusion protein which includes a maltose binding protein (MBP) can be readily purified on an amylose column.
  • a fusion protein which includes protein A may be readily separated using an Ig sepharose column.
  • a preferred nucleotide sequence of the invention comprises a sequence which comprises part or all of the altered sequence shown in Figure 1 (SEQ ID NO 2) as well as sequences which hybridise to such sequences under stringent conditions, other than wild-type sequences.
  • Codon changes may be introduced into the DNA sequence of a wild-type gene which expresses a DNA site-specific nuclease using site directed mutagenesis techniques which are well known in the art.
  • the DNA sequence may be constructed entirely or partly synthetically, also as is conventional in the art.
  • the invention further provides a process for producing a DNA structure-specific nuclease which comprises transforming host cells with an expression vector which includes a nucleotide sequence as described above, culturing said cell and recovering DNA structure-specific nuclease produced.
  • Expression vectors including such sequences as well as host cells transformed with said nucleotide sequence form further aspects of the invention.
  • Host cells may be prokaryotic such as bacterial cells for instance E. coli or eukaryotic cells such as mammalian cell lines, yeast or fungal cells.
  • the invention also provides a DNA structure-specific nuclease which is encoded by a nucleotide sequence as described above.
  • mutant resolving enzymes which express to higher levels can be used in any application for the wild-type enzymes as described above.
  • the catalytically inactive non-cleaving mutants have a possible use for the detection of mismatches in a different way. As has been suggested (Dean supra) if such a mutant binds to a mismatch without cleavage, an antibody directed against the protein would allow detection of the mismatch in a microtitre well thus removing the need for electrophoretic separation.
  • Figure 1 shows the gene sequence of wild-type T4 endonuclease VII (SEQ ID NO 1) and the changes introduced in order to produce a synthetic gene (encoding wild-type protein) to serve as a starting point for generating mutants (SEQ ID NO 2) ;
  • FIG. 1 illustrates the elements used in gene design
  • Figure 3 shows maps of the plasmids used in the preparation of mutant nucleases
  • Figure 4 shows gel electrophoresis of endonuclease VII E86A.
  • Track 1 shows a mixture of proteins serving as molecular weight standards (molecular weights indicated at left in kDa) .
  • Track 2 shows protein A-endonuclease VII E86A (calculated molecular weight 36kDa) ;
  • Track 3 shows oligohistidine-endonuclease VII E86A (calculated molecular weight 20kDa) and
  • track 4 shows endonuclease VII E86A with oligohistidine peptide removed (calculated molecular weight 18 kDa) ;
  • Figure 5 shows a map of endonuclease VII showing three potential structural domains.
  • a N-terminal zinc-binding domain a C-terminal domain with sequence similarity to T4 endonuclease V, and a central domain with some sequence similarity to the functionally related T7 endonuclease I .
  • the latter region may form a significant part of the active site of the protein and contains the E86A mutation;
  • Figure 6 shows a plasmid generated by the gene encoding endonuclease VII E86A being subcloned into pQE30;
  • Figure 7 shows a map of endonuclease VII showing the location of point mutants identified in Table I .
  • Figure 8 Binding isotherms for endonuclease VII and derived mutant proteins binding to a four-way DNA junction. Extent of protein binding to four-way junctions as a function of total protein concentration was estimated by gel electrophoresis. The fraction of DNA junction bound to protein was calculated for each protein concentration, and plotted against the protein concentration (calculated for a dimeric species, M)on a logarithmic scale. The data were fitted to a model for the binding process (see below) , from which the binding affinities were calculated. The points plotted are experimental data, and the lines are simulations derived using the association constants derived from the fits.
  • Example 1 A synthetic gene encoding T4 endonuclease VII
  • a gene was constructed from synthetic DNA to express T4 endonuclease VII in Escherichia coli. The purpose was two-fold. To increase levels of protein expression by optimised codon choice, and to introduce unique restriction sites throughout the gene to facilitate mutagenesis.
  • the complete gene sequence is presented in Figure 1, with the changes introduced into the synthetic gene shown below the wild-type sequence. A total of 53 codons were changed from the wild-type T4 sequence. The major changes were in the leucine codons where the TTR and CTA codons (18 codons) , were replaced by CTG, CTT or CTC. 17 restriction sites were created within the gene.
  • the gene was designed in 6 elements as shown in Figure 2. To allow expression of each part of the gene separately, a methionine codon was added at the N-terminal end and a stop codon at the C-terminal end, as well as a factor Xa cleavage site (the sequence IEGR) . Restriction sites at the 5' and 3' ends were added to enable initial cloning into pAT153. Each part was constructed with two oligonucleotides (for D and F elements) or four oligonucleotides (elements A, B, C, E) . These oligonucleotides ranged in size from 52 to 108 bases.
  • T4 endonuclease VII in _.. coli In order to examine numerous mutants of endonuclease VII an acceptable level of expression together with a simple purification procedure was sought. A tightly controlled expression system was also used, because of the toxicity of the protein in bacterial cells. (Kosak, H.G. et al., Eur. J. Biochem. (1990) , 194, 779-784) . To facilitate purification over expression systems that produce translational fusions with peptides, enabling purification using a single step of affinity chromatography were employed. Two such systems were employed, with fusions to protein A and the maltose binding protein (MBP) .
  • MBP maltose binding protein
  • the vector pMAL-p (Maina CV. , et al, Gene (1988) , 74, 365-373) contains the inducible P tac promoter controlling the expression of a malE-lacZa fusion.
  • the signal sequence of the malE gene directs the synthesised protein into the cell periplasm.
  • a cloning site is located in a linker between the malE gene and the lacZa sequence, which also includes a cleavage site for the protease factor Xa.
  • the plasmid carries the lacl gene encoding the Lac repressor. Expression of the fusion protein is induced by addition of IPTG to the growth medium.
  • the synthetic endonuclease VII gene was recovered from pATSEVII by digestion with BamHI and inserted into the two BamHI sites of the polylinker.
  • the ligated plasmid was transformed into E. coli TBI.
  • the plasmid map is shown in Figure 3A. Cells containing the plasmid were induced with IPTG, broken open by sonication and the protein purified by chromatography on an amylose resin column.
  • the plasmid pK19PRA (Zueco et al. , Anal. Biochem.
  • E. coli strains JM101 and TBI containing recombinant pK19 or pMAL-p plasmids respectively were grown at 37 * C to an absorbance of 0.6 at 660 nm from inoculation of 1 li of LB medium supplemented with 1 mM ZnCl 2 and the appropriate antibiotic.
  • Transcription of the T4 endonuclease VII gene was induced by addition of IPTG to a final concentration of 1 mM and incubation for a further 2 hours at 37 * C
  • the cells were harvested by centrifugation and resuspended in 400 ml of 30 mM Tris, HCl (pH8) , 20% sucrose. EDTA was added to a final concentration of 1 mM and the mixture incubated for 5-10 min at room temperature. After centrifugation at 10,000 rpm for 20 min at 4 * C, the supernatant was removed and the pellet resuspended in 400 ml of ice-cold 5 mM MgS0 4 and incubated for 10 min in an ice bath.
  • the sample was then centrifuged as before, the pellet resuspended in 8 ml 0.5 M sodium phosphate (pH 7.2) and loaded on an amylose resin column eluted under gravity. After washing the column with three volumes of 10 mM sodium phosphate (pH 7.2) , 0.5M NaCl, 10 mM ⁇ -mercaptoethanol, 1 mM EGTA, 0.25 % Tween and five volumes of 10 mM sodium phosphate (pH 7.2) 0.5M NaCl, 10 mM ⁇ -mercaptoethanol, 1 mM EGTA, the protein was eluted with 10 mM maltose in 10 mM phosphate buffer (pH 7.2) , 0.5 M NaCl. 1 mM EGTA. Fractions containing the protein were pooled and the solution dialysed in 50 mM Tris.HCl (pH7.6) 1 mM DTT and 50% glycerol for 2 h
  • Endonuclease VII-E86A as an oligohistidine fusion protein was prepared from 1 litre of E. coli strain M15 (pREP4) transformed with pQE30EVII-E86A.
  • the cells were grown to an A660 of 0.5 and then induced with IPTG to a final concentration of 1 mM for 2 hours. Cells were harvested and lysed as above.
  • the protein was purified by affinity chromatography using nickel- TA (nitrilo-tri-acetate) resin (Qiagen) .
  • the cell extract was applied to the column in 50 mM phosphate, pH 8.0, 300 mM NaCl, and eluted using a gradient of imidazole from 0-500 mM in the same buffer plus 5% glycerol.
  • Oligohistidine-endonuclease VII-E86A elutes in approximately 250 mM imidazole. Following this step the protein is usually >70% pure.
  • the oligohistidine sequence was removed by digestion with 1:500 (w/w) Factor Xa protease at 4°C for 16 h.
  • the resulting endonuclease VII-E86A was purified by chromatography on a Mono-S column.
  • T4 endonuclease VII H38T Over expression of T4 endonuclease VII H38T: a low toxicity mutant Wild-type T4 endonuclease VII is highly toxic when over expressed in E. coli , and can only be expressed to low levels as a consequence. In the course of analysing the role of histidine residues by mutation, one with considerably lowered toxicity was found which can be expressed to higher levels. This mutant has histidine 38 changed to threonine. Despite the reduced toxicity, the enzyme is fully active as MBP and protein A fusions. For example, the rate constants for cleavage of DNA junctions at O'C were found to be the same for mutant and wild-type enzyme, within the experimental error imposed by protein concentration determination. T4 endonuclease VII H38T therefore has the significant practical advantages of over expression to much larger levels without any detectable alteration in properties below 30°C.
  • Mutagenesis Site-directed mutagenesis was performed using the method of Kunkel (1985) (Proc. Natl. Acad. Sci. USA 82, 488-492), which involves the use of single-stranded template DNA that contains a small percentage of uracil bases in place of thymine generated in dut ung E. coli (Strain CJ236) DNA synthesis from a mutagenic primer using normal deoxyribonucleoside triphosphates regenerates the double-stranded plasmid in which the parental strand contains dU. Transformation into a dut* ung * strain leads to selective degradation of this strand, and repair synthesis of the plasmid effectively enriches for the mutagenised strand. Yields of up to 90% of the desired mutants were achieved.
  • pUC119SEVII was transformed into E. coli strain CJ236 (dut ung) .
  • Single-stranded DNA was prepared by transfection of a 100 ml culture of CJ236 containing pUC119SEVII in LB supplemented with appropriate antibiotics by helper phage M13K07. This was incubated at 37°C overnight with vigorous shaking to ensure good aeration.
  • the culture was harvested by centrifugation at 15,000 rpm at 4°C, and the supernatant was decanted into 0.25 volumes of phage-precipitation solution (3.75 M ammonium acetate, pH 8.0, 20% polyethylene glycol (MW 8,000)) , mixed well, and left on ice for 30 minutes. After centrifugation, the pellet was resuspended in 400 ⁇ l of TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) . The phage were lysed by the addition of 400 ⁇ l of chloroform: isoamyl alcohol (24:1) followed by vortexing for 1 min. The solution was centrifuged for 5 min in an Eppendorf centrifuge, and the upper aqueous phase was extracted with phenol/chloroform until there was no material visible at the interface. The upper phase containing the DNA was recovered by precipitation with ethanol.
  • a mutagenic oligonucleotide was designed to effect the change of glutamate 86 to alanine in the gene for endonuclease VII.
  • the sequence was
  • Second-strand synthesis was performed by the addition of 10 ⁇ l of PE3 buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM DTT, 5 mM dNTPs) , 5 U T4 DNA ligase and 3 U T4 DNA polymerase for 5 min on ice, 5 min at room temperature, 2 h at 37°C and finally overnight at room temperature. Half of this mixture was transformed (Cohen, et al.,Proc.
  • the BamHI fragment of pK19SEVII-E86A was excised and ligated into the BamHI site in the multiple cloning region of plasmid pQE30 (Bujard, et al., (1987)Meth. Enzymol. 155, 416-433) (Quiagen), to generate PQE30EVII-E86A.
  • This was transformed into E. coli strain M15 (pREP4) .
  • the resulting colonies were screened for the presence of the insertion, and the orientation of the insertion was determined by restriction analysis (data not shown) . Positive colonies were used for subsequent preparations of the mutant protein.
  • Endonuclease VII E86A was cloned as a translational fusion with proteinA in the plasmid pK19PRA, transformed in E. coli JM101.
  • the gene was under the control of the lac promoter, and was induced by addition of IPTG.
  • the cell lysate was applied to an IgG-sepharose column and the fusion protein eluted in 0.5 M acetic acid, pH 3.4.
  • the peak fraction was then applied to a Mono-S ion exchange column and eluted with a gradient of NaCl.
  • the purity of the protein was analysed by polyacrylamide gel electrophoresis in a buffer containing SDS, and found to contain a single polypeptide migrating at the position expected for a calculated mass of 36 kDa ( Figure 4).
  • Endonuclease VII E86A was also expressed as a fusion with an oligohistidine sequence (6 consecutive N-terminal histidine residues) .
  • the complete coding sequence including the cleavage site for Factor Xa protease, was excised from pK19SEVII-E86A and ligated into the vector pQE30 (Bujard, et al., supra), to give a single translational reading frame that included the oligohistidine sequence ( Figure 5) .
  • the gene is transcribed from a T5 promoter, under the control of two lac operator sequences.
  • the resulting plasmid (pQE30EVII-E86A) ( Figure 6) was transformed into 5 E.
  • oligohistidine-endonuclease VII E86A was purified by chromatography on a nickel-containing
  • the endonuclease VII E86A (as fusions with either protein 25. A or oligohistidine peptide, or following removal of the oligohistidine peptide) failed to cleave four-way DNA junctions under any conditions tested (data not shown) . However, while not cleaving DNA junctions, both proteinA-endonuclease VII E86A and endonuclease VII E86A 30 acted as a inhibitors of active proteinA-endonuclease VII H38T enzyme. In the absence of other proteins, proteinA-endonuclease VII H38T cleaves a four-way DNA junction as observed previously for active endonuclease VII preparations.
  • the ratio of DNA junction and 35 proteinA-endonuclease VII H38T was kept constant, and increasing concentrations of endonuclease VII E86A were added to the incubation. As the concentration of the inactive endonuclease VII E86A increased, the extent of cleavage diminished, eventually leading to complete suppression of the cleavage reaction. This indicates that endonuclease VII E86A competes for substrate with the active enzyme. These results are consistent with a normal binding of DNA by the inactive mutant, thus preventing access by the catalytically active protein (proteinA- endonuclease VII H38T) .
  • Colorimetry (All mutants measured this way) Colorimetric assays were performed as described by Giedroc et al. Proc. Natl. Acad. Sci. USA. 83, (1986). The proteins were dialysed for two hours in 20 M Tris.HCl (pH 8), 600 mM NaCl and 5% glycerol. 4-(2-pyridylazo) resorcinol (PAR) was added to a final concentration of 0.1 mM to 800 ⁇ l of protein solution ranging from 1 to 2 ⁇ M. The protein-resorcinol solution was titrated with p- hydroxymercuriphenylsulphonic acid (PMPS) .
  • PMPS p- hydroxymercuriphenylsulphonic acid
  • PMPS is a reducing agent that binds to the cysteine residues and therefore releases the zinc.
  • the zinc released by PMPS is then chelated by the resorcinol in the solution.
  • the titration is followed by measuring the absorbance of Zn(II)PAR 2 at 500nm (Hunt et al, J. Biol. Chem. 259, 1984) . When this absorbance reaches a plateau, indicating that all the zinc has been released, the concentration of protein bound zinc can be calculated by using a titration of standard ZnCl 2 solutions with resorcinol obtained under the same conditions. Absorption measurements were performed on a CARY IE UV- visible spectrophotometer using 1 ml polystyrene cuvettes.
  • Atomic absorption spectroscopy (H41T measured this way as check on the other method) 1.5 ml of a solution of each protein at a concentration ranging between 1 and 5 ⁇ M was dialysed overnight in 200 mM NaCl, 20 mM Tris.HCl (pH 8), 1 mM DTT. Spectroscopy was performed on a UNICAM 939/959 atomic absorption spectrometer equipped with a zinc lamp, using an acetylene flame.
  • Varying amounts of each mutant and wild-type protein were incubated with 24.2 nM [5 32 P]labelled junction for 10 min at room temperature in lO ⁇ l of binding buffer 50 mM Tris- HCl (pH7.4), 100 mM NaCl, 1 mM dithiothreitol and either 1 mM EDTA or 200 ⁇ M MgCl 2 .
  • K D the dissociation constant

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à des protéines spécifiques de la structure de l'ADN. De manière spécifique, cette invention se rapporte à une séquence nucléotidique codant des nucléases spécifiques de la structure de l'ADN ayant été modifiées de sorte qu'un codon soit changé pour au moins un acide aminé de telle sorte que la nucléase codée par la séquence nucléotidique soit moins toxique envers une cellule hôte que ladite enzyme de type sauvage, et/ou de telle sorte que ladite nucléase ne possède pas l'activité catalytique de l'enzyme de type sauvage mais conserve ses caractéristiques de liaison à l'ADN, concernant la sélectivité vis à vis de la structure, de l'enzyme de type sauvage.
PCT/GB1996/002218 1995-09-08 1996-09-09 Nucleases specifiques de la structure de l'adn WO1997009434A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68862/96A AU6886296A (en) 1995-09-08 1996-09-09 Dna structure-specific nucleases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9518382.8 1995-09-08
GBGB9518382.8A GB9518382D0 (en) 1995-09-08 1995-09-08 Novel enzymes
GB9614111.4 1996-07-05
GBGB9614111.4A GB9614111D0 (en) 1996-07-05 1996-07-05 Novel enzymes

Publications (1)

Publication Number Publication Date
WO1997009434A1 true WO1997009434A1 (fr) 1997-03-13

Family

ID=26307712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002218 WO1997009434A1 (fr) 1995-09-08 1996-09-09 Nucleases specifiques de la structure de l'adn

Country Status (2)

Country Link
AU (1) AU6886296A (fr)
WO (1) WO1997009434A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110684A (en) * 1998-02-04 2000-08-29 Variagenics, Inc. Mismatch detection techniques
WO2001005800A2 (fr) * 1999-07-18 2001-01-25 Borries Kemper Procede d'enrichissement d'heteroduplexes et son utilisation dans la detection de mutations
WO2001062968A2 (fr) * 2000-02-25 2001-08-30 General Atomics Enzymes de liaison nucleique mutantes et leur application dans le diagnostic, la detection et la purification
EP1185675A1 (fr) * 2000-03-31 2002-03-13 Korea Advanced Institute of Science and Technology Souche d'escherichia coli secretant le facteur stimulant les colonies de granulocytes humains (g-csf)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308762A (en) * 1989-09-01 1994-05-03 Vanderbilt University T4 endonuclease V DNA repair enzyme having specific activity at low salt concentrations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308762A (en) * 1989-09-01 1994-05-03 Vanderbilt University T4 endonuclease V DNA repair enzyme having specific activity at low salt concentrations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANAMITRA BHATTACHARYYA ET AL.: "Model for the interaction of DNA junctions and resolving enzymes", JOURNAL OF MOLECULAR BIOLOGY, vol. 221, no. 4, 1991, pages 1191 - 1207, XP000612384 *
DAVID SHORTLE ET AL.: "Genetic analysis of staphylococcal nuclease: Identification of three intragenic "global" supressors of nuclease-minus mutations", GENETICS, vol. 110, no. 4, August 1995 (1995-08-01), pages 539 - 555, XP002022251 *
DEREK R. DUCKETT ET AL.: "Binding of the junction-resolving enzyme bacteriophage T7 endocnuclease I to DNA: Separation of binding and catalysis by mutation", THE JOURNAL OF MOLECULAR BIOLOGY, vol. 246, 10 February 1995 (1995-02-10), pages 95 - 107, XP000612465 *
DUCKETT D R ET AL: "Binding of the junction-resolving enzyme T7 endonuclease I to DNA: Separation of binding and catalysis by mutation.", KEYSTONE SYMPOSIUM ON REPAIR AND PROCESSING OF DNA DAMAGE, TAOS, NEW MEXICO, USA, MARCH 23-29, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21A). 1995. 317. ISSN: 0733-1959, XP000611963 *
GIRAUD-PANIS, MARIE-JOSEPHE E. ET AL: "The modular character of a DNA junction-resolving enzyme: a zinc-binding motif in bacteriophage T4 endonuclease VII", J. MOL. BIOL., 252(5), 596-610 CODEN: JMOBAK;ISSN: 0022-2836, 6 October 1995 (1995-10-06), XP000612466 *
JÖRG TOMASCHEWSKI ET AL.: "Nucleotide sequence and primary structures of gene products coded for by the T4 genome between map positions 48.266 kb and 39.166 kb", NUCLEIC ACIDS RESEARCH, vol. 15, no. 8, 1987, OXFORD GB, pages 3632 - 3633, XP002022252 *
POHLER, J. RICHARD G. ET AL: "T4 endonuclease VII selects and alters the structure of the four-way DNA junction;binding of a resolution-defective mutant enzyme", J. MOL. BIOL. (1996), 260(5), 678-696 CODEN: JMOBAK;ISSN: 0022-2836, 2 August 1996 (1996-08-02), XP000612456 *
THOMAS OELGESCHLÄGER ET AL.: "Probing the function of individual amino acid residues in the DNA binding site of the EcoRI restriction endocnuclease by analysing the toxicity of genetically engineered mutants", GENE, vol. 89, no. 2, 14 May 1990 (1990-05-14), AMSTERDAM NL, pages 19 - 27, XP002022249 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110684A (en) * 1998-02-04 2000-08-29 Variagenics, Inc. Mismatch detection techniques
EP1053352A1 (fr) * 1998-02-04 2000-11-22 Variagenics, Inc. Procedes de detection d'un mauvais appariement
EP1053352A4 (fr) * 1998-02-04 2001-03-21 Variagenics Inc Procedes de detection d'un mauvais appariement
WO2001005800A2 (fr) * 1999-07-18 2001-01-25 Borries Kemper Procede d'enrichissement d'heteroduplexes et son utilisation dans la detection de mutations
WO2001005800A3 (fr) * 1999-07-19 2001-05-10 Borries Kemper Procede d'enrichissement d'heteroduplexes et son utilisation dans la detection de mutations
WO2001062968A2 (fr) * 2000-02-25 2001-08-30 General Atomics Enzymes de liaison nucleique mutantes et leur application dans le diagnostic, la detection et la purification
WO2001062968A3 (fr) * 2000-02-25 2002-08-08 Gen Atomics Enzymes de liaison nucleique mutantes et leur application dans le diagnostic, la detection et la purification
EP1185675A1 (fr) * 2000-03-31 2002-03-13 Korea Advanced Institute of Science and Technology Souche d'escherichia coli secretant le facteur stimulant les colonies de granulocytes humains (g-csf)
EP1185675A4 (fr) * 2000-03-31 2004-05-12 Korea Advanced Inst Sci & Tech Souche d'escherichia coli secretant le facteur stimulant les colonies de granulocytes humains (g-csf)

Also Published As

Publication number Publication date
AU6886296A (en) 1997-03-27

Similar Documents

Publication Publication Date Title
Hall et al. Evidence for a physical interaction between the Escherichia coli methyl‐directed mismatch repair proteins MutL and UvrD
Martin et al. Mutational analysis of mammalian poly (A) polymerase identifies a region for primer binding and catalytic domain, homologous to the family X polymerases, and to other nucleotidyltransferases.
Nishi et al. An eIF-4A-like protein is a suppressor of an Escherichia coli mutant defective in 50S ribosomal subunit assembly
JP2021192624A (ja) 特定のゲノム遺伝子座へのゲノムおよびエピゲノム調節タンパク質のｒｎａ誘導型標的化
Llosa et al. Functional domains in protein TrwC of plasmid R388: dissected DNA strand transferase and DNA helicase activities reconstitute protein function
Garinot-Schneider et al. Identification of putative active-site residues in the DNase domain of colicin E9 by random mutagenesis
Kim et al. Biotin tagging deletion analysis of domain limits involved in protein-macromolecular interactions: mapping the τ binding domain of the DNA polymerase III α subunit
WO2001073079A2 (fr) Proteines chimeres permettant de detecter et de quantifier des mutations d'adn, des variations de sequences d'adn, des dommages a l'adn et des incompatibilites d'adn
Grütter et al. Structural studies of mutants of the lysozyme of bacteriophage T4: the temperature-sensitive mutant protein Thr157→ Ile
Tirumalai et al. Recognition of core-type DNA sites by λ integrase
GB2233977A (en) Cysteine-free streptolysin O
Wu et al. In vitro gamma-carboxylation of a 59-residue recombinant peptide including the propeptide and the gamma-carboxyglutamic acid domain of coagulation factor IX. Effect of mutations near the propeptide cleavage site.
Jourdan et al. Mutational analysis of the transcriptional regulator GcvA: amino acids important for activation, repression, and DNA binding
WO1997009434A1 (fr) Nucleases specifiques de la structure de l'adn
Kawasaki et al. Folding-Dependentin VitroProtein Splicing of theSaccharomyces cerevisiae VMA1Protozyme
WO1996040882A1 (fr) Endonuclease artificielle de restriction
Gu et al. Single amino acid changes alter the repair specificity of Drosophila Rrp1. Isolation of mutants deficient in repair of oxidative DNA damage.
Steffen et al. Purification and characterization of the single-stranded DNA binding protein from Streptococcus pneumoniae
Gupta et al. Co-expressed recombinant human Translin-Trax complex binds DNA
US8163521B2 (en) Self-assembled proteins and related methods and protein structures
Ichiyanagi et al. Mutational analysis on structure–function relationship of a Holliday junction specific endonuclease RuvC
JP3498808B2 (ja) Ｄｎａポリメラーゼ遺伝子
US20230416708A1 (en) Novel Variants of Endonuclease V and Uses Thereof
JP3688367B2 (ja) 変異型ｄｎａポリメラーゼ
US5731185A (en) Isolated DNA encoding the hphi restriction endonuclease and related methods for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA